PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Kosei Hirakawa Selected Research
Neoplasm Metastasis (Metastasis)
03/2008
Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
11/2007
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.
08/2007
A synergistic antitumor effect of interleukin-2 addition with CD80 immunogene therapy for peritoneal metastasis of gastric carcinoma.
12/2006
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
12/2005
Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
08/2005
Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma.
05/2005
[A case of anthracycline and taxane-resistant breast cancer with life-thereatening multiple liver metastases responding to oral combination chemotherapy by UFT, cyclophosphamide and medroxyprogesterone acetate]
02/2004
[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum]
01/2004
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
12/2003
Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role in tumor invasion and metastasis.
10/2003
[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer]
09/2003
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer]
01/2003
Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum.
08/2002
Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.
05/2002
Prognostic value of combined analysis of estrogen receptor status and cellular proliferative activity in breast cancer patients with extensive lymph node metastases.
Articles by Research Topic
Disease
15
Neoplasm Metastasis (Metastasis)
03/2008 - 05/2002
14
Stomach Neoplasms (Stomach Cancer)
12/2007 - 02/2004
7
Carcinoma (Carcinomatosis)
05/2008 - 01/2003
7
Neoplasms (Cancer)
11/2007 - 12/2003
7
Pancreatic Neoplasms (Pancreatic Cancer)
01/2007 - 12/2003
6
Colorectal Neoplasms (Colorectal Cancer)
03/2008 - 10/2003
5
Colonic Neoplasms (Colon Cancer)
06/2008 - 08/2002
4
Breast Neoplasms (Breast Cancer)
05/2005 - 05/2002
2
Crohn Disease (Crohn's Disease)
09/2008 - 03/2008
2
Esophageal Neoplasms (Esophageal Cancer)
09/2005 - 10/2003
1
Ascites
11/2006
1
Hyperaldosteronism (Conn Syndrome)
08/2006
1
Atrophy
07/2006
1
Infection
07/2006
1
Microsatellite Instability
03/2006
1
Thyroid Neoplasms (Thyroid Cancer)
12/2002
Drug/Important Bio-Agent (IBA)
6
Cyclooxygenase 2 (Cyclooxygenase-2)
IBA
03/2008 - 08/2002
5
Cisplatin (Platino)
FDA Link
Generic
12/2007 - 02/2004
4
Fluorouracil (Carac)
FDA Link
Generic
09/2005 - 10/2003
3
titanium silicide (TS-1)
IBA
07/2005 - 02/2004
2
Epidermal Growth Factor Receptor (EGF Receptor)
IBA
06/2008 - 02/2005
2
pyrimidine
IBA
12/2007 - 03/2004
2
Ki23057
IBA
11/2007 - 11/2006
2
Vascular Endothelial Growth Factor C
IBA
06/2007 - 01/2003
2
Protease Inhibitors (Protease Inhibitor)
IBA
01/2007 - 08/2004
2
gemcitabine
FDA Link
08/2006 - 06/2005
2
trastuzumab (Herceptin)
FDA Link
08/2006 - 10/2003
2
Cyclophosphamide (Cytoxan)
FDA Link
Generic
05/2005 - 07/2003
2
Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
IBA
11/2004 - 01/2004
2
Estrogens (Estrogen)
FDA Link
01/2004 - 05/2002
2
Pyrimidines
IBA
01/2004 - 09/2003
1
Ghrelin
IBA
09/2008
1
gefitinib (Iressa)
FDA Link
06/2008
1
Phosphotransferases (Kinase)
IBA
05/2008
1
Transforming Growth Factor beta Receptors (TGF beta Receptors)
IBA
05/2008
1
Endothelin Receptors (Endothelin Receptor)
IBA
03/2008
1
Endothelin-converting enzyme 1
IBA
03/2008
1
Histones (Histone)
IBA
11/2007
1
Interleukin-2 (IL2)
IBA
08/2007
1
Transforming Growth Factor beta (TGF-beta)
IBA
02/2007
1
Enzymes
IBA
11/2006
1
irinotecan (Camptosar)
FDA Link
Generic
11/2006
1
Paclitaxel (Taxol)
FDA Link
Generic
11/2006
1
DNA (Deoxyribonucleic Acid)
IBA
09/2006
1
Histone Deacetylases (Histone Deacetylase)
IBA
09/2006
1
trichostatin A (A 300)
IBA
09/2006
1
Pepsinogen A (Pepsinogen)
IBA
07/2006
1
Mucins
IBA
01/2006
1
Plasminogen Activators (Plasminogen Activator)
IBA
12/2005
1
Interferons
IBA
09/2005
1
Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
IBA
08/2005
1
docetaxel (Taxotere)
FDA Link
07/2005
1
Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
IBA
07/2005
1
taxane
IBA
05/2005
1
Medroxyprogesterone 17-Acetate (Depo-Provera)
FDA Link
Generic
05/2005
1
Coenzyme A (CoA)
IBA
07/2004
1
monoacetoacetin
IBA
07/2004
1
succinyl-coenzyme A (succinyl-CoA)
IBA
07/2004
1
Transferases
IBA
07/2004
1
Telomerase (Telomerase Reverse Transcriptase)
IBA
01/2004
1
Progesterone Receptors (Progesterone Receptor)
IBA
01/2004
1
Fibroblast Growth Factor 7
FDA Link
12/2003
1
Trypsinogen
IBA
12/2003
1
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
IBA
09/2003
1
PPAR gamma
IBA
12/2002
Therapy/Procedure
2
Combination Drug Therapy (Combination Chemotherapy)
05/2005 - 07/2003
1
Adrenalectomy
08/2006
1
Gastroenterostomy
03/2006
1
Gastrectomy
03/2006
1
Immunotherapy
01/2006
1
Drug Therapy (Chemotherapy)
10/2003